{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:11:24Z","timestamp":1788869484247,"version":"build-2803163510"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"S2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although systemic therapy for patients with metastatic renal cell carcinoma (mRCC) was once limited to the cytokines interleukin-2 and interferon (IFN)-\u03b1, in recent years several targeted therapies have become available for first- and second-line use. These include sorafenib, sunitinib, bevacizumab (plus IFN-\u03b1), temsirolimus, everolimus, and, most recently, pazopanib. This expanded list of treatment options arose from molecular biological research that revealed aberrant signal transduction activities in RCC, enabling the identification of specific molecular targets for therapy. Molecular-targeted therapies have better efficacy and tolerability than cytokine therapy, and many are administered orally. The superior outcomes achieved with molecular-targeted agents are prompting investigators to reconsider overall survival as a primary endpoint in clinical trials, given the inherent complications of a required long duration of follow-up, a required large population, and confounding caused by crossover trial designs or effects of subsequent therapy after progression on the agent of interest. In mRCC trials, progression-free survival has become a popular primary endpoint and has served as the basis of approval for several targeted therapies. In addition to the identification of new agents, current research is focused on the evaluation of combination therapy with targeted agents. As more information regarding mechanisms of disease and drug resistance becomes available, new targets, new targeted agents, and new combinations will be studied with the goal of providing maximal efficacy with minimal toxicity. This article reviews the clinical evidence supporting the benefits of targeted agents in mRCC treatment, discusses survival endpoints used in their pivotal clinical trials, and outlines future research directions.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-s2-14","type":"journal-article","created":{"date-parts":[[2011,2,23]],"date-time":"2011-02-23T11:52:34Z","timestamp":1298461954000},"page":"14-22","source":"Crossref","is-referenced-by-count":136,"title":["Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence"],"prefix":"10.1093","volume":"16","author":[{"given":"Thomas E.","family":"Hutson","sequence":"first","affiliation":[{"name":"Baylor Sammons\/Texas Oncology, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"2021122304143693100_B1","volume-title":"NCCN Clinical Practice Guidelines in Oncology\u2122. Kidney Cancer","author":"National Comprehensive Cancer Network"},{"issue":"suppl 10","key":"2021122304143693100_B2","doi-asserted-by":"crossref","first-page":"x25","DOI":"10.1093\/annonc\/mdm411","article-title":"Treatment options in renal cell carcinoma: Past, present and future","volume":"18","author":"Oudard","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122304143693100_B3","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.1999.17.7.2039","article-title":"Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?","volume":"17","author":"Escudier","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122304143693100_B4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.2011-S2-04","article-title":"Tumor biology and prognostic factors in renal cell carcinoma","volume":"16","author":"Finley","year":"2011","journal-title":"The Oncologist"},{"key":"2021122304143693100_B5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/j.1464-410X.2009.08987.x","article-title":"Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: Differences and synergies of two targeted mechanisms","volume":"104","author":"Mulders","year":"2009","journal-title":"BJU Int"},{"key":"2021122304143693100_B6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122304143693100_B7","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B8","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122304143693100_B10","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"2021122304143693100_B11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B12","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2009.26.5561","article-title":"Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206","volume":"28","author":"Rini","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B13","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B14","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122304143693100_B15","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"2021122304143693100_B16","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B17","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","article-title":"Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma","volume":"17","author":"Motzer","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B18","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"2021122304143693100_B19","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"2021122304143693100_B20","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122304143693100_B21","first-page":"281s","article-title":"Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone [abstract 5127]","volume":"26","author":"Dutcher","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B22","volume-title":"Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial [abstract 283]","author":"Bhargava","year":"2009"},{"issue":"15 suppl","key":"2021122304143693100_B23","first-page":"366s","article-title":"Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT) [abstract 4599]","volume":"28","author":"Bhargava","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122304143693100_B24","first-page":"247s","article-title":"A phase I\/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results [abstract 3057]","volume":"28","author":"Angevin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122304143693100_B25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1634\/theoncologist.13-S2-19","article-title":"Endpoints for assessing drug activity in clinical trials","volume":"13","author":"Pazdur","year":"2008","journal-title":"The Oncologist"},{"key":"2021122304143693100_B26","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0b013e3181b9c5ec","article-title":"Progression-free survival: Gaining on overall survival as a gold standard and accelerating drug development","volume":"15","author":"Lebwohl","year":"2009","journal-title":"Cancer J"},{"key":"2021122304143693100_B27","volume-title":"Progression-free survival (PFS) as a predictor of overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy [abstract 329]","author":"Heng","year":"2010"},{"key":"2021122304143693100_B28","volume-title":"Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) [abstract 385]","author":"Halabi","year":"2010"},{"issue":"15 suppl","key":"2021122304143693100_B29","first-page":"258s","article-title":"A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial [abstract 5099]","volume":"27","author":"Procopio","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B30","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1200\/JCO.2007.11.1047","article-title":"Sorafenib with interferon alfa-2b as first-line treatment of advanced renal cell carcinoma: A phase II study of the Southwest Oncology Group","volume":"25","author":"Ryan","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B31","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1200\/JCO.2007.10.8613","article-title":"Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer","volume":"25","author":"Gollob","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122304143693100_B32","first-page":"259s","article-title":"Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-\u03b12a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681 [abstract 5100]","volume":"25","author":"Bracarda","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B33","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2007.10.8332","article-title":"Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity","volume":"26","author":"Azad","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B34","volume-title":"Study Comparing Bevacizumab + Temsirolimus vs Bevacizumab + Interferon-Alfa in Advanced Renal Cell Carcinoma Subjects (INTORACT)"},{"key":"2021122304143693100_B35","volume-title":"Bevacizumab, Sorafenib, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer"},{"key":"2021122304143693100_B36","volume-title":"Combination of Temsirolimus and Bevacizumab in Patients with Metastatic Renal Cell Carcinoma (TORAVA)"},{"key":"2021122304143693100_B37","volume-title":"Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer"},{"issue":"15 suppl","key":"2021122304143693100_B38","first-page":"672s","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma [abstract 16020]","volume":"26","author":"Fischer","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B39","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1158\/1078-0432.CCR-09-0717","article-title":"A phase I study of sunitinib plus bevacizumab in advanced solid tumors","volume":"15","author":"Rini","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"18 suppl","key":"2021122304143693100_B40","first-page":"259s","article-title":"Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract 5099]","volume":"25","author":"Feldman","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B41","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.eururo.2009.01.001","article-title":"Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: A case series","volume":"56","author":"Medioni","year":"2009","journal-title":"Eur Urol"},{"issue":"15 suppl","key":"2021122304143693100_B42","first-page":"244s","article-title":"Phase I\/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients [abstract 5039]","volume":"27","author":"Merchan","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122304143693100_B43","first-page":"259s","article-title":"A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma [abstract 5104]","volume":"27","author":"Harzstark","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122304143693100_B44","first-page":"243s","article-title":"Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma [abstract 5037]","volume":"27","author":"Kroog","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"2021122304143693100_B45","first-page":"714s","article-title":"Phase II study of everolimus (E) with imatinib (IM) in patients with previously-treated renal carcinoma (RCC) [abstract e16075]","volume":"27","author":"Ryan","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122304143693100_B46","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","article-title":"Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma","volume":"28","author":"Hainsworth","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-S2-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-S2-14","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/S2\/14\/41855143\/oncolo_16_s2_14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/16\/S2\/14\/41855143\/oncolo_16_s2_14.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T08:13:03Z","timestamp":1640247183000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/16\/S2\/14\/6401769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":46,"journal-issue":{"issue":"S2","published-online":{"date-parts":[[2011,2,1]]},"published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-s2-14","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,2,1]]},"published":{"date-parts":[[2011,2,1]]}}}